Immunologic aspects of multiple sclerosis

Physical Medicine and Rehabilitation Clinics of North America

Volumn 9, Issue 3, 1998, Pages 525-536

  Taylor, R S ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2; METHOTREXATE; MYELIN; ROLIPRAM; ROQUINIMEX; SOMATOMEDIN; STEROID; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ASTROCYTE; AUTOIMMUNE DISEASE; CYTOKINE RELEASE; DRUG INDICATION; GEOGRAPHIC DISTRIBUTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0031721286     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1047-9651(18)30246-8     Document Type: Review

References (36)

1. Archelos J.J. Jung S. Maurer M. Inhibition of EYE by an antibody to the Intracellular Adhesion Molecule (ICAM-1) Ann Neurol 35 1993 145 154
2. Brosnan F. Bornstein M.D. Bloom B.R. The effects of macrophage depletion on the clinical and pathologic expression of EAE J Immunol 126 1981 614 620
3. Bruck W. Schmied M. Suchaneic G. Oligodendrocytes in the early course of MS Ann Neurol 35 1994 65 73
4. Coyle P.K. The neuroimmunologic basis of MS/Advances in neuromuscular immunology 6 1996 143 154
5. Cross A.H. Miskotp Linrf Aminoguanadine, an inhibitor of inducible nitric oxide synthetase ameliorates EAE in SUL mice J Clin Invest 93 1984 2684 2690
6. Dore-Duffy P. Newman W. Ballanov R. Circulating soluble adhesion proteins in CSF and serum of patients with MS correlation with clinical activity Ann Neurol 37 1995 55 62
7. Ebers G.C. Sadounk A.D. Rischen J. A genetic basis for familial aggregation in MS Nature 377 1995 150 151
8. Gallo P. Pizzinzo N.G. Tavlato B. A longitudinal study of interleukin 2, interleukin 4 and gamma interferon in multiple sclerosis cerebral spinal fluid and serum J Neurol Sci 101 1991 227 232
9. Hohlfeld R. Meinle Webber F. The role of autoimmune T lymphocytes in the pathogenesis of MS Neurology 45 1995 S33 S38
10. Hohlfeld R. Proinflammatory cytokines and the immunogenic basis of MS Abram-sky O. Frontiers in MS 1997 Mosby London 149 155
11. Hohlfeld R. Mein L.E. Webber F. The role of autoimmune T lymphocytes in the pathogenesis of MS Neurology 45 1995 S33 S38
12. Hohlfeld R. Neurological auto-immune disease and the tri-molecular complex of T lymphocytes Ann Neurol 25 1989 531 538
13. Kurtzke J.F. Halliph J.F. Tourtellate W.E. Epidemiology of MS 1983 Williams and Wilkins MS. Baltimore 49 95
14. Link J. Soderstrom M. Lungdahl B. Organ specific autoantigens including interferon gamma and interleukin 4, messenger rna expression in mononuclear cells in multiple sclerosis Neurology 44 1994 728 734
15. Lossinsky A.S. Badmayevv Robson J.A. Sites of egress of inflammatory cells and horseradish peroxidase transport across the blood brain barrier in a murine model of EAE Acta Neurologica 78 1989 359 371
16. Lucchinetti C.F. Rodriguez M. The controversy surrounding the pathogenesis of the MS lesion Mayo Clinic Proceedings 72 1997 665 678
17. McHugh S.M. Rifkin I.R. Deighton J. The immunosuppressive drug thalidomide induces T helper type and concomitantly inhibits TH1 cytokine production on antigen stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 99 1995 160 167
18. Mokhtarian F. Shiy Shirazian D. Defective production of anti-inflammatory cytokine TGF-beta by T cell lines of patients with active MS J Immunol 152 1994 6003 6010
19. Navikas V. Link H. Review, Cytokines and the Pathogenesis of Multiple Sclerosis J Neurosci Res 45 1996 322 333
20. Navikas J. Unk H. Review Cytolines and the Pathogenesis of MS J Neurosci Res 45 1996 322 333
21. Navikas J. Link H. Review, cytokines and the pathogenesis of MS J Neurosci Res 45 1996 322 333
22. Panitch H.S. Hersch R.L. Schindler J. Treatment of MS with gamma interferon: Exacerbations associated with activation of the immune system Neurology 37 1987 1047 1102
23. Poser C.M. The role of trauma in the pathogenesis of MS Clin Neurol Neurosurg 96 1994 103 110
24. Prineas J.W. Bernard R.O. Kwon E.E. MS remyelination of nascent lesions Ann Neurol 33 1993 137 151
25. Rickman M.P. Albrecht M. Kitze B. Cytokine RNA levels in mononuclear clear blood cells from patients with MS Neurology 44 1994 1523 1526
26. Rickman N.P. Albrecht M. Kilze B. Tumor Necrosis Factor Alpha, Messenger expression in patients with relapsing and remitting MS is associated with disease activation Ann Neurol 37 1995 182 188
27. Schluessner H.J. Transforming growth factor beta suppresses astrocyte auto antigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by IFN gamma and TNF J Neuroimmunol 27 1990 41 47
28. Selmaj K. Rain E.S. Tumor necrosis factor mediated myelin in oligodendrocyte damage in vitro Ann Neurol 23 1988 339 346
29. Smith M.E. Gibs M.A. Forn L.S. H3 thymidine labeling of astrocytes in EAE J Neuroimmunol 15 1987 309 321
30. Somner N. Loschman P. Northoff G. The antidepressant rolipram suppresses cytokine production and prevents EYE Nat Med 1995 244 248
31. Somner N.N. Martin R. the role of T cells and cytokines in the pathogenesis of MS Thompson MS clinical challenges and controversies 1997 Mosby London 87 101
32. Sriram M.D. Rodriguez M. Indictment of the microglia as the villain of MS Neurology 48 1997 464 470
33. Wikerle H. Kojimak Lannes V. Animal models of multiple sclerosis Ann Neurol 36 1994 S47 S53
34. Williams K.C. Ulvestade Hrcheyn Immunology of MS Clin Neurosci 2 1994 229 245
35. Williams K.C. Ulvestade Hickey W.D. Immunology of MS Clin Neurosci 2 1994 229 249
36. Yednock T.B. Cannon C. Fritz L.C. Prevention of EAE Nature 356 1992 63 66